| Date Filed | Type | Description |
| 11/20/2020 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/07/2018 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/13/2017 |
D
| Form D - Notice of Exempt Offering of Securities |
| 02/11/2015 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 10/04/2013 |
D/A
| Form D - Notice of Exempt Offering of Securities [amend] |
| 07/19/2013 |
D
| Form D - Notice of Exempt Offering of Securities |
| 10/05/2012 |
8-K
| Quarterly results |
| 09/12/2012 |
8-K
| Entry into a Material Definitive Agreement |
| 08/10/2012 |
10-K
| Annual Report for the period ended June 30, 2010 |
| 06/07/2012 |
8-K
| Form 8-K - Current report |
| 01/10/2012 |
8-K
| Form 8-K - Current report |
| 09/28/2010 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 09/07/2010 |
8-K
| Form 8-K - Current report |
| 07/06/2010 |
8-K
| Form 8-K - Current report |
| 05/17/2010 |
10-Q
| Quarterly Report for the period ended March 31, 2010 |
| 05/04/2010 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"Amendment dated April 19, 2010by and between Urigen Pharmaceuticals, Inc. and Platinum-Montaur Life Sciences, LLC",
"Certificate of designation of the relative rights and preferencesOf theSeries C Convertible Preferred Stock filed with the Secretary of State of Delaware on April 21, 2010",
"Warrant issued to Platinum-Montaur Life Sciences, LLC",
"Source: Urigen Pharmaceuticals, Inc. On Monday April 26, 2010, 9:25" |
|
| 04/23/2010 |
BW
| Urigen Files Request for FDA Meeting |
| 04/12/2010 |
BW
| Presentation by Lowell Parsons, MD Now on Urigen.com |
| 03/22/2010 |
3
| Vickery Dan B (Director) has filed a Form 3 on Urigen Pharmaceuticals, Inc. |
| 03/18/2010 |
BW
| Urigen CEO Interview on Urigen.com |
| 03/03/2010 |
8-K
| Form 8-K - Current report |
| 03/03/2010 |
BW
| Edward R. Teitel, MD, JD Becomes Chairman of Urigen |
| 02/22/2010 |
BW
| Lowell Parsons, MD To Make Urigen Presentation in Atlanta |
| 02/17/2010 |
BW
| William K. Schmidt, PhD Joins Urigen's SAB |
| 02/16/2010 |
10-Q
| Quarterly Report for the period ended December 31, 2009 |
| 01/15/2010 |
8-K
| Form 8-K - Current report |
| 12/31/2009 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 12/21/2009 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Consulting Agreement between Urigen Pharmaceuticals, Inc. and Oceana Therapeutics",
"Urigen & Oceana Collaborate on FDA Meeting Preparation SAN FRANCISCO, Dec. 21, 2009 -- Urigen Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101. "Oceana has expertise in developing and commercializing drugs which are delivered procedurally, including in urology," said Urigen’s CEO William J. Garner, MD. “This allows Urigen to move URG101 forward with a talented potential partner to prepare for an FDA meeting.” David S. Tierney, M.D., President and COO, Oceana Therapeutics said, “We’re excited about the potential of URG10..." |
|
| 12/07/2009 |
8-K
| Appointed a new director |
| 11/16/2009 |
10-Q
| Quarterly Report for the period ended September 30, 2009 |
| 10/29/2009 |
8-K
| Form 8-K - Current report |
| 10/28/2009 |
8-K
| Form 8-K - Current report |
| 10/13/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 09/24/2009 |
10-K
| Annual Report for the period ended June 30, 2009 |
|